High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m(2), days 1, 15, 29), high-dose methotrexate (3 g/m(2) days 2, 16,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritsch, K, Kasenda, B, Schorb, E, Hau, P, Bloehdorn, J, Möhle, R, Löw, S, Binder, M, Atta, J, Keller, U, Wolf, H-H, Krause, S W, Heß, G, Naumann, R, Sasse, S, Hirt, C, Lamprecht, M, Martens, U, Morgner, A, Panse, J, Frickhofen, N, Röth, A, Hader, C, Deckert, M, Fricker, H, Ihorst, G, Finke, J, Illerhaus, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/
https://www.ncbi.nlm.nih.gov/pubmed/27843136
http://dx.doi.org/10.1038/leu.2016.334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/
https://www.ncbi.nlm.nih.gov/pubmed/27843136
http://dx.doi.org/10.1038/leu.2016.334

Ejemplares similares